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EDITORIAL
The blind men and the elephant
The first modern clinicopathologic description of fo-
cal segmental glomerulosclerosis (FSGS) by Churg
et al for the International Study of Kidney Dis-
ease in Children included four cases that “contained
epithelial crescents in addition to variable mesangial pro-
liferation and sclerosis” [1]. The authors concluded that
these small crescents were different from the large, oc-
cluding crescents seen in rapidly progressive glomeru-
lonephritis. The proliferating epithelial cells seen in some
cases of FSGS were initially identified as podocytes
by basement membrane attachment or contiguity with
identifiable podocytes even when their appearance was
altered by the nuclear and cytoplasmic changes that char-
acterize FSGS [2]. However, this method has its limits
because the proliferating epithelial cells are loosely co-
hesive, often are detached in Bowman’s space, and fre-
quently are continuous with the parietal epithelium via
adhesions.
The cellular origin of epithelial proliferation in FSGS
has remained a focus of investigation with conflicting re-
sults. Podocytes lose the ability to enter the cell cycle dur-
ing embryonic life, and the demonstration of epithelial
proliferation in Bowman’s space suggests that some form
of injury leads to a new podocyte phenotype. In addi-
tion to mitotic activity, the proliferating epithelial cells do
not generally express mature podocyte markers [Glepp1,
synaptopodin, vimentin, WT-1, CALLA (CD10), C3b re-
ceptor, podocalyxin, and PHM-5] [3, 4]. In addition, they
demonstrate phenotypic markers not seen in podocytes,
including cytokeratin [4–6] and the CD68 marker for
macrophages [2]. These investigations [3–8] were per-
formed on the proliferating epithelial cells in patients
with primary FSGS, but none of the studies were able
to identify the cells, definitively, as podocytes. In con-
trast, Hara et al [9] found that injured podocytes from
patients with primary FSGS retained their staining for
podocalyxin, even when disrupted and excreted in the
urine. Thus, some of the cells in Bowman’s space may
be injured, phenotypically altered podocytes, but based
upon marker studies, the parietal epithelium and facul-
tative macrophages also appear to contribute to the “ex-
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tracapillary” lesion. In spite of these conflicting data, the
growing evidence supporting a central role for podocyte
injury in the pathogenesis of FSGS has continued to fa-
vor the podocyte as the cell of origin for the proliferating
cells. Diverse pathologic processes, including podocyte
transdifferentiation [8], dysregulation [3], and epithelial
mesenchymal transformation [6] explain the disparity be-
tween the immunohistochemical profile of podocytes and
the proliferating cells. Each investigator focuses on his
own data, and like the blind men who describe the ele-
phant in the poem by John Godfrey Saxe, “The dispute
was loud and long, each in his own opinion exceeding stiff
and strong, though each was partly in the right. . .all were
in the wrong.”
In this issue of Kidney International, Dijkman et al
[10] make significant contributions to our understand-
ing of the origin of the proliferating epithelial cells in
FSGS. The authors studied the glomerular pathology in
a kidney from a patient with recurrent FSGS in a renal
transplant by serial sections, marker analysis, and three-
dimensional reconstruction of glomeruli. Because the eti-
ology is presumably the same, recurrent FSGS provides
a unique model of primary FSGS in human beings. The
proliferating cells did not stain for the podocyte markers
synaptopodin, CD10, vimentin, and vascular endothe-
lial growth factor (VEGF), but they did stain for CK8,
a marker of parietal cell activation, and PAN cadherin
and PAX-2, which stain normal parietal epithelium. In
double staining experiments, cells identified as podocytes
by in situ hybridization for the podocyte marker VEGF
did not stain for CK8. Furthermore, the extracellular ma-
trix in the segmental lesions resembled Bowman’s cap-
sule basement membrane [collagen a1 (IV) and heparan
sulfate 4E4 positive] rather than glomerular basement
membrane [collagen a3 (IV) and heparan sulfate 4C3
negative]. Three-dimensional reconstruction of involved
glomeruli demonstrated that CK8-positive cells in Bow-
man’s space and within the central tuft were always in
continuity with the CK8-positive cells lining Bowman’s
capsule. These observations support the origin of the pro-
liferating cells in FSGS from the parietal epithelium lining
Bowman’s capsule.
It has been suggested that the collapsing variant
of FSGS has a different pathogenic mechanism from
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classic FSGS because epithelial proliferation occurs
without formation of adhesions [11]. In the case of recur-
rent FSGS studied by Dijkman et al [10], the segmental
lesions were classified as collapsing FSGS because they
contained areas of capillary collapse and epithelial hy-
perplasia. Serial sectioning of involved glomeruli demon-
strate that the lesions often contained contiguous foci
with different pathologic appearances, including isolated
capillary collapse with epithelial hyperplasia, endocap-
illary foam cells and adhesions, and advanced sclero-
sis. These results suggest that the histologic variants
described in FSGS [12] are stages in the evolution of the
glomerular lesion and not independent lesions.
Dijkman et al [10] acknowledge that they do not ad-
dress the etiology of the proliferative lesion, and that the
results do not challenge the primary role of podocyte in-
jury in the pathogenesis of FSGS. The conclusions are
based upon studies in only one patient, but the results
appear to resolve the conflicting literature by demonstrat-
ing that the proliferating cells in FSGS in human beings
physically originate from, and have the histochemical and
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